The compound, NP16, inhibits the MRSA-produced staphyloxanthin, which can resist the human immune system. This allows the body to overcome MRSA and mitigate it.
For the study, researchers examined the effects of NP16 in infected mice. They found the use of MP16 caused MRSA bacteria levels to fall by a factor of 10 within a few days. Additionally, they found the compound was not toxic to human cells.
The researchers claim this is the first study to use chemical genetics to treat MRSA, and they are now looking to see if similar approaches could help fight other superbugs, such as drug-resistant E. coli, according to the report.
More articles on healthcare quality:
Researchers develop diagnostic tool for Parkinson’s detection
5 things to know about clinical nurse specialists
CDC activates Emergency Operations Center for Harvey response
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
